| 596 | 6 | 16 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：研究卡格列净通过肾素血管紧张素系统（RAS）和转化生长因子-β1(TGF-β1)对自发性高血压大鼠（SHR）心室重构的影响。方法：本实验分为正常血压大鼠（WKY）组、SHR组、卡格列净低剂量[SHR-CANA(30 mg/kg)]组及卡格列净高剂量[SHR-CANA(60 mg/kg)]组，每组8例，采用灌胃法给药，1次/d，连续8周。测定血压（BP）、血糖水平，采用超声心动图评价动物心功能，采用组织形态学评价动物左心室细胞面积。实时定量聚合酶链反应和蛋白印记杂交法检测Ⅰ型胶原（Col1a）、Ⅲ型胶原（Col3a）、基质金属蛋白酶2(MMP-2)、TGF-β1、Smad4、肾素、血管紧张素Ⅱ受体1(AGTR1)和血管紧张素Ⅱ受体2(AGTR2)的表达。结果：给药8周后，SHR-CANA(30 mg/kg)组及SHR-CANA(60 mg/kg)组的心脏体重/体重比（HW/BW）、左心室重量/心脏重量比（LVW/HW）、心肌细胞面积与SHR组比较，差异有统计学意义（P<0.05）。与SHR组相比，SHR-CANA(30 mg/kg)组及SHR-CANA(60 mg/kg)组的血压、血糖和体重明显降低。与SHR组相比，SHR-CANA(30 mg/kg)组及SHR-CANA(60 mg/kg)组Col1a、Col3a、MMP2、TGF-β1、Smad4、Renin、AGTR1表达显著下调，AGTR2表达上调。结论：卡格列净可通过调节RAS和TGF-β1/Smad信号通路改善高血压诱导的心脏重构。
Abstract：Objective:The objective of the present work was to study the effect of canagliflozin,a sodium – glucose co-transporter 2 inhibitor(SGLT-2i)on myocardial remodeling through renin angiotensin system(RAS)and transforming growth factor-β1(TGF-β1)in spontaneously hypertensive rats(SHR). Methods:SHRs were administered with canagliflozin once a day at a dose of 30 and 60 mg/kg body weight through an oral gavage for 8 weeks respectively. Wistar-Kyoto rats(WKY)were served as control. Blood pressure(BP)was determined by tail-cuf sphygmomanometry. Blood glucose level was measured by glucometer.The heart function of animals was evaluated by echocardiography and the degree of ventricular hypertrophy were evaluated by histomorphology. Expression collagen Ⅰ（Col1a）,collagen Ⅲ（Col3a）,matrix metalloproteinase 2(MMP-2),TGF-β1,Smad4,Renin,angiotensin Ⅱ type 1 receptor(AGTR1)and angiotensin Ⅱ type 2 receptor(AGTR2)was detected by real-time quantitative polymerase chain reaction and western blotting.Results:After 8 weeks of treatment,a significant difference was observed in the heart weight/body weight(HW/BW)ratio,left ventricle weight/heart weight(LVW/HW)ratio and cardiomyocyte area between canagliflozin treatment group and SHR. A significant decrease in BP,blood glucose and body weight of canagliflozin treatment group compared to SHRs was observed. The expression of col1a,col3a,MMP2,TGF-β1,Smad4,renin,AGTR1 was downregulated significantly in canagliflozin treatment group compared to SHRs,while expression of AGTR2 was upregulated.Conclusion:From the results,canagliflozin was found to ameliorate pressure overload-induced cardiac remodeling by regulating the RAS and TGF-β1/Smad signaling pathway.
1 Huang CY,Nithiyanantham S,Liao JY,et al.Bioactive peptides attenuate cardiac hypertrophy and fibrosis in spontaneously hypertensive rat hearts[J].Food Drug Anal,2020,28(1):94-102.
2 Sainsily X,Coquerel D,Giguere H,et al.Elabela protects spontaneously hypertensive rats from hypertension and cardiorenal dysfunctions exacerbated by dietary high-salt intake[J].Front Pharmacol,2021,12:709467.
3 Zhang W,Wang Q,Feng Y,et al.Micro RNA-26a protects the heart against hypertension-induced myocardial fibrosis[J].Am Heart Assoc,2020,9(18):e017970.
4 Zhang Y,Su SA,Li W,et al.Piezo1-mediated mechanotransduction promotes cardiac hypertrophy by impairing calcium homeostasis to activate calpain/calcineurin signaling[J].Hypertension,2021,78(3):647-660.
5 Michel MC,Brunner HR,Foster C,et al.Angiotensin II type 1 receptor antagonists in animal models of vascular,cardiac,metabolic and renal disease[J].Pharmacol Therapeut,2016,164:1-81.
6 Adamcova M,Kawano I,Simko F.The impact of micrornas in renin-angiotensin-system-induced cardiac remodelling[J].Int J Mol Sci,2021,22(9):4762.
7 Anavekar NS,Solomon SD.AngiotensinⅡreceptor blockade and ventricular remodelling[J].JRenin-Angio-Aldo S,2005,6(1):43-48.
8 Bockmann I,Lischka J,Richter B,et al.FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis[J].Int J Mol Sci,2019,20(18):4634.
9 Dopona E,Rocha VF,Furukawa L,et al.Myocardial hypertrophy induced by high salt consumption is prevented by angiotensinⅡAT2 receptor agonist[J].Nutr Metab Cardiovasc Dis,2019,29(3):301-305.
10 Hanna A,Humeres C,Frangogiannis NG.The role of Smad signaling cascades in cardiac fibrosis[J].Cell Signal,2021,77:109826.
11 Jekell A,Nilsson PM,Kahan T.Treatment of hypertensive left ventricular hypertrophy[J].Curr Pharm Design,2019,24(37):4391-4396.
12 Liakos CI,Papadopoulos DP,Sanidas EA,et al.Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors,GLP-1 receptor agonists,and DPP-4 inhibitors)[J].Am J Cardiovasc Drug,2021,21(2):123-137.
13 Ramirez AJ,Sanchez MJ,Sanchez RA.Diabetic patients with essential hypertension treated with amlodipine[J].J Hypertens,2019,37(3):636-642.
14 Matsutani D,Sakamoto M,Kayama Y,et al.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes[J].Cardiovasc Diabetol,2018,17(1):73.
15 Hasan R,Lasker S,Hasan A,et al.Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways[J].Sci Rep-Uk,2020,10(1):14459.
16 Sun P,Wang Y,Ding Y,et al.Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the m TOR/HIF-1αpathway[J].Science,2021,24(6):102521.
17 Sayour A A,Korkmaz-Ic?z S,Loganathan S,et al.Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation[J].J Transl Med,2019,17(1):127.
18 Li C,Zhang J,Xue M,et al.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J].Cardiovasc Diabetol,2019,18(1):15.
19 Lee HC,Shiou YL,Jhuo SJ,et al.The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats[J].Cardiovasc Diabetol,2019,18(1):45.
20 Ji W,Zhao M,Wang M,et al.Effects of canagliflozin on weight loss in high-fat diet-induced obese mice[J].PLo S One,2017,12(6):e0179960.
21 Chen MB,Wang H,Cui WY,et al.Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus[J].Medicine,2021,100(6):e24593.
22 Wei D,Liao L,Wang H,et al.Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARαin vivo and in vitro[J].Life Sciences,2020,247:117414.
23 Neal B,Perkovic V,Mahaffey KW,et al.Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes[J].New Engl J Med,2017,377(7):644-657.
24 Ashry NA,Abdеlaziz RR,Suddеk GM,et al.Canagliflozin ameliorates aortic and hepatic dysfunction in dietary-induced hypercholesterolemia in the rabbit[J].Life Sci,2021,280:119731.
25 El-Daly M,Pulakazhi Venu VK,Saifeddine M,et al.Hyperglycaemic impairment of PAR2-mediated vasodilation:Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress[J].Vasc Pharmacol,2018,109:56-71.
26 Lim VG,Bell RM,Arjun S,et al.SGLT2 Inhibitor,canagliflozin,attenuates myocardial infarction in the diabetic and nondiabetic heart[J].JACC:Basic Transl Sc,2019,4(1):15-26.
27 Liang Y,Arakawa K,Ueta K,et al.Effect of canagliflozin on renal threshold for glucose,glycemia,and body weight in normal and diabetic animal models[J].PLo S One,2012,7(2):e30555.
28 González A,Ravassa S,López B,et al.Myocardial remodeling in hypertension[J].Hypertension,2018,72(3):549-558.
29 Shi L,Zhu D,Wang S,et al.Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload[J].Am J Hypertens,2019,32(5):452-459.
30 Zhang Y,Lin X,Chu Y,et al.Dapagliflozin:A sodium-glucose cotransporter 2 inhibitor,attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling[J].Cardiovasc Diabetol,2021,20(1):121.
31 Park SH,Farooq MA,Gaertner S,et al.Empagliflozin improved systolic blood pressure,endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat[J].Cardiovasc Diabetol,2020,19(1):19.
32 Mclarty JL,Meléndez GC,Brower GL,et al.Tryptase/protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts[J].Hypertension,2011,58(2):264-270.
33 Zhai Y,Gao X,Wu Q,et al.Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-β1/Smad 7 expression in the spontaneously hypertensive rats[J].Eur J Pharmacol,2008,587(1-3):196-203.
34 Nelson AR,Fingleton B,Rothenberg ML,et al.Matrix Metalloproteinases:Biologic activity and clinical implications[J].J Clin Oncol,2000,18(5):1135-1149.
35 Matsusaka H,Ide T,Matsushima S,et al.Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload[J].Hypertension,2006,47(4):711-717.
36 Mujumdar VS,Smiley LM,Tyagi SC.Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength[J].Int J Cardiol,2001,79(2-3):277-286.
37 Zavadzkas JA,Plyler RA,Bouges S,et al.Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice[J].Am J Physiol Heart Circ Physiol,2008,295(4):H1394-H1402.
38 Rosenkranz S,Flesch M,Amann K,et al.Alterations ofβ-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1[J].Am J Physiol Heart C,2002,283(3):H1253-H1262.
39 Brooks WW,Conrad CH.Myocardial fibrosis in transforming growth factor beta(1)heterozygous mice[J].JMol Cell Cardiol,2000,32(2):187-195.
40 Zhao M,Zhang J,Xu Y,et al.Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy,Fibrosis,and Inflammation[J].Int Immunopharmacol,2021,99:108046.
41 Zong J,Zhang H,Li FF,et al.NLRP1 promotes TGF-beta1-induced myofibroblast differentiation in neonatal rat cardiac fibroblasts[J].Mol Histol,2018,49(5):509-518.
42 Huang Y,Qi Y,Du JQ,et al.Micro RNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4[J].Expert Opin Ther Targets,2014,18(12):1355-1365.
43 Zhang LH,Pang XF,Bai F,et al.Preservation of glucagon-like peptide-1 level attenuates angiotensin ii-induced tissue fibrosis by altering AT1/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart[J].Cardiovasc Drugs Ther,2015,29(3):243-255.
44 Katayama IA,Pereira RC,Dopona EP,et al.High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation[J].J Nutr,2014,144(10):1571-1578.
45 Zhang T,Tang N,Xi D,et al.Calcimimetic R568 improved cardiac remodeling by classic and novel renin-angiotensin system in spontaneously hypertensive rats[J].Exp Biol Med,2019,244(10):789-801.
基本信息:
DOI：10.13210/j.cnki.jhmu.20220407.003
中图分类号:R542.2
引用信息:
[1]李爱花,王青青,秦迎春,等.卡格列净通过RAS和TGF-β1/Smad途径减轻高血压诱导的心肌肥厚和纤维化[J].海南医学院学报,2022,28(13):966-975.DOI:10.13210/j.cnki.jhmu.20220407.003.
基金信息:
国家自然科学基金资助项目(31570949)~~
2022-04-08
2022-04-08
2022-04-08